OT

OS Therapies Incorporated

OSTX·NYSE

$1.42

-2.1%
HealthcareBiotechnology

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$50.00M
EPS-0.5200
P/E Ratio-2.73
Earnings Date03/30/2026

ostx

Total Other Income Expenses Net

Last Annual Value

-2.07M

3-Year CAGR

7%

5-Year CAGR

-459%

10-Year CAGR

-136%

OT

OS Therapies Incorporated Competitors Analysis of Total Other Income Expenses Net

OSTX · NYSE
CompanyTotal Other Income Expenses Net
CAGR 3Y
CAGR 5Y
CAGR 10Y
-2.07M
N/AN/AN/A 
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
1.94M
-30.0%69.7%N/A
MNOV logo
MediciNova, Inc.
NASDAQ:MNOV
1.29M
-1.0%72.7%52.0%
64.11M
272.2%244.6%N/A
419.00K
-33.4%55.6%145.8%
125.64K
N/AN/AN/A
-145.00K
N/AN/AN/A
-2.45M
N/AN/AN/A
766.31K
50.5%5.1%N/A
-12.40M
N/AN/AN/A
3084.97B
N/AN/AN/A
OT

OS Therapies Incorporated Fair Value Envelope

OSTX · NYSE

Our analysis suggests that OSTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.42, this represents a potential HIDDEN relative to our calculated worth for OS Therapies Incorporated.

Intrinsic Value
Current Price: $1.42